FDA approval for Ascendis

The FDA has approved Ascendis’ Yorvipath, a hormone replacement therapy to treat hypoparathyroidism. Ascendis was ready to bring the drug to the market 15 months ago but was rejected due to a manufacturing problem. Then 3 months ago things were delayed when the FDA said they needed additional time to make its decision. Initial supplies should be available in the first quarter of 2025.